Comprehensive epithelial biomarker analysis of malignant mesothelioma: EpCAM positivity is a potential diagnostic pitfall
- 17 April 2023
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 131 (8) , 507-515
Abstract
Background: Epithelial cell adhesion molecule (EpCAM) is frequently used to distinguish carcinoma from background mesothelial cells during cytologic examination of body cavity fluids. Previously, the authors identified one malignant mesothelioma case with strong and diffuse membranous EpCAM staining, making it indistinguishable from carcinoma.Methods: In this study, the authors evaluated all available effusion specimens from patients with malignant mesothelioma, including the above‐mentioned index case, obtained at Stanford Health Care, from 2011 to 2021 (N = 17) as well as control cases (N = 5). Analyses included an immunohistochemistry (IHC) assay for EpCAM and claudin‐4, a multiplexed immunofluorescent (IF) assay for EpCAM, and an RNA in situ hybridization assay targeting EpCAM.Results: The authors detected EpCAM positivity of variable intensity and percentage in four malignant mesothelioma cases (23.5%; although only two showed positivity for the epithelial‐specific IHC marker MOC31 in ≥40% of cells) and claudin‐4 negativity in all cases, with two cases displaying focal and weak claudin‐4 staining in <1% of cells. Multiplexed IF staining on the cases with EpCAM IHC positivity showed strong, membranous EpCAM staining in one of four cases. RNA in situ hybridization also was used to assess the correlation between EpCAM positivity by IHC/IF and RNA expression levels. Strong EpCAM RNA expression was detected in the three malignant mesothelioma cases.Conclusions: The current findings revealed that a subset of epithelioid malignant mesothelioma cases mimic or exhibit the immunophenotypic features of carcinoma when evaluating for EpCAM only. Additional biomarker testing, such as claudin‐4, may help avoid this potential pitfall to yield accurate diagnoses.Keywords
This publication has 17 references indexed in Scilit:
- Immunocytochemical utility of claudin‐4 versus those of Ber‐EP4 and MOC‐31 in effusion cytologyDiagnostic Cytopathology, 2016
- Circulating tumor cell technologiesMolecular Oncology, 2016
- Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesotheliomaAnnals of Diagnostic Pathology, 2015
- Claudin‐4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytologyCancer Cytopathology, 2014
- RNAscopeThe Journal of Molecular Diagnostics, 2012
- Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistryDiagnostic Cytopathology, 2010
- Utility of WT‐1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusionsDiagnostic Cytopathology, 2007
- Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificityLaboratory Investigation, 2006
- The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative studyLaboratory Investigation, 2006
- Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluidsDiagnostic Cytopathology, 2005